Modular Medical, Inc.

Modular Medical, Inc. is a medical device company that designs, develops, and commercializes innovative insulin pumps. The company focuses on using modernized technology to increase pump adoption in the diabetes marketplace. Modular Medical aims to alter the trade-offs between cost, complexity, and access to high standards of care through an innovative two-part patch pump. This approach seeks to simplify the user experience from initial product introduction, prescription assistance, insurance reimbursement, streamlined training, and day-to-day use with clinical support. The company intends to expand the wearable insulin delivery device market beyond highly motivated "super users" into the mass market. Its products target both type 1 and type 2 diabetes markets for individuals requiring multiple daily doses of insulin. In January 2024, Modular Medical submitted a 510(k) premarket notification to the United States Food and Drug Administration (FDA) for its initial insulin pump product, the MODD1. In September 2024, the company received FDA clearance to market and sell the MODD1 pump in the United States. In August 2025, Modular Medical announced the first human use of its MODD1 pump delivering insulin to a human patient. Also in August 2025, the company announced its next-generation patch pump, branded as Pivot™, and began converting its cartridge manufacturing line to Pivot production. The Pivot product is a tubeless insulin delivery system that integrates the infusion set under the removable pump into a true tubeless patch. The Pivot is expected to provide cost and usability improvements and improved manufacturability. Modular Medical submitted a 510(k) premarket notification to the FDA for its Pivot product in November 2025, and in April 2026, received FDA clearance to market and sell the Pivot pump in the United States. The company does not intend to commercialize its MODD1 product.